Traws Pharma (NASDAQ:TRAW) Trading 2.5% Higher – Here’s What Happened

Traws Pharma, Inc. (NASDAQ:TRAW) shot up 2.5% on Thursday . The stock traded as high as $2.69 and last traded at $2.49. 208,866 shares traded hands during trading, a decline of 33% from the average session volume of 310,677 shares. The stock had previously closed at $2.43.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. HC Wainwright initiated coverage on Traws Pharma in a report on Wednesday, December 3rd. They issued a “buy” rating and a $8.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Traws Pharma in a research report on Monday, December 22nd. Zacks Research upgraded shares of Traws Pharma to a “hold” rating in a research note on Thursday, December 4th. Finally, Wall Street Zen lowered shares of Traws Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.00.

Traws Pharma Stock Down 2.8%

The firm has a fifty day moving average price of $1.88 and a two-hundred day moving average price of $1.91. The stock has a market capitalization of $19.34 million, a P/E ratio of 0.02 and a beta of 1.66.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($9.16) by $8.82. Traws Pharma had a net margin of 3,028.25% and a negative return on equity of 2,883.04%.

Institutional Investors Weigh In On Traws Pharma

A hedge fund recently raised its stake in Traws Pharma stock. Two Sigma Investments LP boosted its holdings in Traws Pharma, Inc. (NASDAQ:TRAW) by 37.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,018 shares of the company’s stock after acquiring an additional 5,955 shares during the quarter. Two Sigma Investments LP owned 0.31% of Traws Pharma worth $41,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.